Russian pharmaceutical market grew by 7% in 2013
The Russian pharmaceutical market is on the verge of stagnation, as in 2013 it grew only by 7%, compared to 2012, which is the lowest growth figure for the last 10 years, according to a recent report from the Russian Ministry of Health.
During the first quarter of 2013 the market grew by 18%, which was mainly due to a flu epidemic in Russia, however during the next three quarters of last year the growth was insignificant, mainly in the retail segment. At the same time segment of hospital drug purchases in 2013 remained at the level of 2012.
According to analysts at the Russian Ministry of Health, in 2013 the level of competition tightened in almost all segments of the market and also among the distributors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze